EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Dual Therapy in Inflammatory Bowel Disease

Gabriele Altieri iD, Alessandra Zilli, Tommaso Lorenzo Parigi, Mariangela Allocca, Federica Furfaro, Gionata Fiorino iD, Clelia Cicerone iD, Laurent Peyrin-Biroulet, Silvio Danese, Ferdinando D'Amico iD

Biomolecules · 03.02.2025 · 15 (2) · 222

DOI: 10.3390/biom15020222 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Biomolecules, online erschienen am 03.02.2025. Verfasst von Gabriele Altieri und 9 weiteren Autor:innen. Beteiligte Einrichtung: Gastroenterology and Endoscopy, IRCCS San Raffaele Hospital, 20132 Milan, Italy. Hauptthemen laut MEDLINE: Inflammatory Bowel Diseases, Biological Products, Colitis, Ulcerative, Crohn Disease. Die Arbeit wurde bisher 25-mal zitiert (Crossref) und nennt 93 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Inflammatory bowel diseases (IBDs), including ulcerative colitis (UC) and Crohn’s disease (CD), are chronic and complex autoimmune conditions. Despite the advancements in biologics and small molecules, the therapeutic ceiling persists, posing significant treatment challenges and contributing to the concept of difficult-to-treat IBD. Dual-targeted therapy (DTT), combining two biologic agents or biologics with small molecules, has emerged as a novel approach to address this unmet need by targeting multiple inflammatory pathways simultaneously. Evidence suggests that DTT holds promise in improving clinical and endoscopic outcomes, especially in patients with refractory disease or extraintestinal manifestations. Safety data, while consistent with monotherapy profiles, highlight the importance of vigilant monitoring for infections and other adverse events. Continued research and high-quality trials are crucial to defining optimal DTT regimens and broadening its clinical applicability. This review explores the efficacy and safety of DTT in IBD, reporting data from clinical trials, systematic reviews, and real-world studies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Inflammatory Bowel DiseasesBiological ProductsColitis, UlcerativeCrohn DiseaseHumansDrug Therapy, Combination

Stichwörter der Autor:innen

Crohn’s diseasecombination therapydual-targeted therapyinflammatory bowel diseaseulcerative colitis

Substanzen

Biological Products

Autor:innen und Institutionen

  • Gastroenterology and Endoscopy, IRCCS San Raffaele Hospital, 20132 Milan, Italy.
  • Faculty of Medicine and Surgery, Vita Salute San Raffaele University, 20132 Milan, Italy.
  • Gastroenterology and Digestive Endoscopy, San Camillo-Forlanini Hospital, 00152 Rome, Italy.
  • Department of Gastroenterology, INFINY Institute, INSERM NGERE, CHRU de Nancy, Université de Lorraine, F-54500 Vandœuvre-lès-Nancy, France.

ORCID-Profile: Gabriele Altieri, Gionata Fiorino, Clelia Cicerone, Ferdinando D'Amico

Zitieren

APA

Altieri, G., Zilli, A., Parigi, T. L., Allocca, M., Furfaro, F., Fiorino, G., Cicerone, C., Peyrin-Biroulet, L., Danese, S., & D'Amico, F. (2025). Dual Therapy in Inflammatory Bowel Disease. Biomolecules, 15(2), 222. https://doi.org/10.3390/biom15020222

Vancouver

Altieri G, Zilli A, Parigi TL, Allocca M, Furfaro F, Fiorino G, et al. Dual Therapy in Inflammatory Bowel Disease. Biomolecules. 2025;15(2):222. doi:10.3390/biom15020222

BibTeX
@article{Altieri2025,
  author = {Altieri, Gabriele and Zilli, Alessandra and Parigi, Tommaso Lorenzo and Allocca, Mariangela and Furfaro, Federica and Fiorino, Gionata and Cicerone, Clelia and Peyrin-Biroulet, Laurent and Danese, Silvio and D'Amico, Ferdinando},
  title = {Dual Therapy in Inflammatory Bowel Disease},
  journal = {Biomolecules},
  year = {2025},
  volume = {15},
  number = {2},
  pages = {222},
  doi = {10.3390/biom15020222}
}
Kostenlos starten →